NZ 596517 Disclosed is a pharmaceutical composition comprising an isolated human anti-TNF? antibody that dissociates from human TNF? with a Kd of 1x10-8M or less and a Koff rate constant of 1x10-3s-1 or less, both determined by surface plasmon resonance, and neutralises human TNF? cytotoxicity in a standard in vitro L929 assay with an IC50 of 1x10-7 M or less, and a pharmaceutically acceptable carrier, wherein the composition contains a level of HCP no greater than 70ng of HCP per mg of antibody as measured by an HCP ELISA and a cathepsin L activity of no greater than 3.0 RFU/s/mg antibody.
